Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Big Pharma seeks long term remission x combining I/O therapy

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 24, 2023 9:34pm

198 Views

Post# 35752481

RE:RE:Big Pharma seeks long term remission x combining I/O therapy

BMS’ solid tumor franchise is heavily focused on immuno-oncology compared with targeted therapies, recently highlighted by the acquisition of KRAS 12C inhibitor from idrug development nnovator Mirati Therapeutics for US$ 5.8 Billion.

Krazati in December 2022 won an FDA accelerated approval for previously treated KRAS G12C-mutant NSCLC.

https://www.fiercepharma.com/pharma/bristol-myers-buys-mirati-58b-i-o-giant-branches-out-targeted-therapy-cancer

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing